This YC biotech startup built a genetic kill switch to end cancer. Here is how 3 Oxford PhDs cracked the platform.

FinalDose is taking on a $5 trillion market by shifting from traditional search-and-edit gene therapies to search-and-destroy target architectures. By combining CRISPR shape-change mechanics with frontier AI models, they prove how hardware constraints dissolve when software timelines hit deeptech.

We sit down with the founders to breakdown their foundational patent, YC batch execution, and the timeline to commercialization.

What you will learn:

- Why 60 years of targeted protein pharma missed the underlying DNA driver signature

- How FinalDose engineered a Cas9 conformational shape change into a cellular kill switch

- The exact framework used to validate their platform in just 40 days during YC

- How AI models collapse drug discovery costs by 10X and accelerate timelines by 3X

- The delivery vectors needed to clear targeted organs like the liver, lung, and skin

- How mutation burden per year dictates the biological ceiling for human longevity

📌 Watch now and subscribe for more smart, fast, founder-first interviews.

00:00 Intro 00:18 The $5 Trillion Thesis: Ending Cancer 02:11 Why 60 Years of Pharma Targeted the Wrong Mechanism 04:08 The Eureka Moment: Turning CRISPR into a Kill Switch 06:12 The AI Unlock: Harnessing Conformational Changes 08:04 How YC Forced a Bio Startup onto Software Timelines 10:14 Defending a Foundational Patent Against Big Pharma 13:16 Solving the Specificity and Delivery Bottlenecks 16:11 Can We Delete DNA Damage to Live 300 Years? 19:15 10x Cheaper, 3x Faster: The New Bio Playbook

🎧 Listen on the go:

Spotify: https://open.spotify.com/show/1u1JyRKH8JYFjhBkvTUOAP

Apple: https://apple.co/4cZ8RMm

My other YouTube Channel: https://www.youtube.com/@lobstercap

This Lobster Talks episode is brought to you by YC Roaster, a free tool helping founders improve their YC applications.

🔗 https://ycroaster.com